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rnal of Stroke and CerBackground: Impaired glucose tolerance (IGT) in patients with ischemic stroke can
return to normal, reflecting an acute stress response, or persist. Persistent IGT is
associated with an increased risk of recurrent stroke, other cardiovascular diseases
and unfavorable outcome after stroke. We aim to validate our previously developed
model to identify patients at risk of persistent IGT in an independent data set, and,
if necessary, update the model. Methods: The validation data set consisted of 239
nondiabetic patients with a minor ischemic stroke or TIA and IGT in the acute
phase (2-hour post-load glucose levels between 7.8 and 11.0 mmol/l). The outcome
was persistent versus normalized IGT, based on repeated oral glucose tolerance test
after a median of 46 days. The discriminative ability of the original model was
assessed with the area under the ROC curve (AUC). The updated model was inter-
nally validated with bootstrap resampling and cross-validated in the development
population of the original model. Results: One-hundred eighteen of 239 (49%)
patients had persistent IGT. The original model, with the predictors age, current
smoking, statin use, triglyceride, hypertension, history of cardiovascular diseases,
body mass index (BMI), fasting plasma glucose performed poorly (AUC .60). The
newly developed model included only BMI, hypertension, statin use, atrial fibrilla-
tion, 2-hour post-load glucose levels, HbA1c, large artery atherosclerosis, and pre-
dicted persistent IGT more accurately (internally validated AUC 0.66, externally
validated AUC .71). Conclusions: This prediction model with simple clinical varia-
bles can be used to predict persistent IGT in patients with IGT directly after minor
stroke or TIA, and may be useful to optimize secondary prevention by early identi-
fication of patients with disturbed glucose metabolism.
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ebrovascular Diseases, Vol.&&, No.&& (&&Introduction
Impaired glucose tolerance (IGT) is an intermediate
metabolic state between normal glucose metabolism and
diabetes mellitus, with a growing prevalence worldwide.
IGT is highly prevalent in patients with recent ischemic
stroke or transient ischemic attack (TIA). This IGT can be
transient, reflecting an acute stress response, or persis-
tent, representing undiagnosed impaired glucose metab-
olism.1 Of nondiabetic stroke patients with IGT in
the acute phase after stroke and repeated glucose assess-
ment after 3 months, 22%-47% has persistent IGT after
3 months.1-4
IGT increases the risk of recurrent stroke and other cardio-
vascular events.5,6 Moreover, IGT is also associated with
poor functional outcome and mortality after stroke.5,7,8), 2020: 104815 1
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be beneficial for these patients, in the acute phase as well as
part of secondary prevention. In a previous study by our
group, we developed a prediction model to identify patients
with persistent impaired glucose tolerance at 3 months after
TIA and ischemic stroke. This prediction model including
age, current smoking, statin use, triglyceride, hypertension,
previous ischemic cardiovascular disease, body mass index,
and fasting plasma glucose accurately predicted persistent
IGT.4 However, this prediction model has not been exter-
nally validated in an independent population.
The aim of our study was to externally validate the
original prediction model and, if necessary, to update the
model to identify patients at risk of persistent IGT after
TIA and minor stroke.
Methods
Study Population
Patients were included if they were 18 years or older
and attended the TIA outpatient clinic, or were admitted
to the stroke unit of Medical Spectrum Twente in
Enschede and Ikazia Hospital in Rotterdam, the Nether-
lands between February 2014 and December 2017. These
patients had a clinical diagnosis of TIA, amaurosis fugax
or minor ischemic stroke (defined as a modified Rankin
scale score of 3 or less) within the previous 6 months.
Written informed consent was obtained from all patients
or a first-degree relative, as approved by the Institutional
Ethics Committee.
Patient Characteristics
Demographic data, vascular history and risk factors,
including statin use, hypertension (defined as previous
use of antihypertensive medication or blood pressure
higher than 140/90 mmHg), current smoking, atrial fibril-
lation, body mass index (BMI), laboratory assessments,
including lipid profile and ischemic stroke subtype
according to the TOAST classification 9 were collected.
Glucose Assessment
In all nondiabetic patients (defined as no use of oral or
parenteral antidiabetic medication), fasting plasma glu-
cose and post-load glucose levels were assessed on the
day of the TIA outpatient clinic visit or the second day of
admission on the stroke unit as part of standard care.
Post-load glucose levels were assessed by performing
the oral glucose tolerance test (OGTT). The OGTT was
performed after overnight fasting, and patients drank a
solution of 75 g glucose in 150 mL water. Eligible
patients were diagnosed with IGT, defined as 2-hour
post-load glucose levels between 7.8 and 11.0 mmol/L.10
The glycosylated hemoglobin A1c levels (HbA1c) were
assessed at the follow-up visit, 2 to 12 weeks after admis-
sion and at 6 months.Outcome Measures
Two to 12 weeks after the initial OGTT, patients with
IGT were asked to undergo a second OGTT. We previ-
ously stated in the study protocol that the OGTT should
be repeated after 2-6 weeks. Due to logistic reasons, this
time frame was extended to 2-12 weeks. Patients with
fasting plasma glucose levels of 7.0 mmol/L or higher
were diagnosed with diabetes and therefore did not
undergo the repeated OGTT.
Based on the results of the second OGTT, patients
were classified in the following 2 groups: normalized
post-load-glucose levels (2-hour post-load-glucose lev-
els < 7.8 mmol/L) or persistent IGT (2-hour post-load
glucose levels  7.8 mmol/L according to international
guidelines ([10]).Statistical Analysis
We used means with standard deviations to describe
normally distributed continuous variables, and medians
and interquartile ranges to describe the non-normally dis-
tributed continuous variables. We compared patient char-
acteristics between glucose groups, with normalized post-
load-glucose levels as a reference. The differences between
categorical variables were tested by chi-square and con-
tinuous variables by Student’s t-test. Non-normally dis-
tributed variables were compared by MannWhitney U-
test. P < .05 was considered to indicate statistical signifi-
cance. Missing data were imputed with single imputation
using baseline characteristics and the outcome variable, if
the frequency was less than 5%. The analysis was carried
out with STATA 12.1 statistical package (Statacorp, Col-
lege Station, Texas) and R statistical software.Model Validation
First, we compared patient characteristics between
the current study and the previous (development
cohort)4 Second, to assess the validity of the original
prediction model, we assessed the effect of the predic-
tors of the original model in the current development
population. As the final validation step, overall model
performance was assessed in terms of discrimination
and calibration. Calibration refers to the agreement
between observed and predicted outcomes. Calibra-
tion plots were used to visualize the observed and pre-
dicted rates. The intercept shows whether predictions
are systematically too low or too high, and should ide-
ally be zero. The calibration slope reflects the average
effects of the predictors in the model, and was esti-
mated in a logistic regression model. In a perfect
model, the slope is 1.
Discrimination refers to the ability to distinguish a
patient with and without persistent IGT, with the use of
the area under the ROC curve (AUC). The AUC ranges
from .5 for noninformative to 1.0 for perfect models.11
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The next, optional third step was to develop a new,
updated model. Possible predictors of persistent IGT
included known risk factors for developing diabetes and
other vascular risk factors according to the previous litera-
ture: age, sex, current smoking, statin use, hypertension, pre-
vious ischemic cardiovascular disease, atrial fibrillation, BMI,
TIA versus ischemic stroke, large artery atherosclerosis, fast-
ing plasma glucose, 2-hour post-load glucose, and HbA1c
levels.1-3,12-15 Large artery atherosclerosis was defined as sig-
nificant (>50%) stenosis or occlusion of a major brain artery
or branch cortical artery, due to atherosclerosis.9
All potential predictors were tested with a multivariable
logistic regression model and tested for the final model with
stepwise backward selection, with a P-value of less than or
equal to .2. The internal validity of the model was assessed
by means of bootstrapping techniques, resulting in an inter-
nally validated AUC. A bootstrap sample means that a ran-
dom sample of the same size of the original population is
drawn with replacement. The model is developed in the
bootstrap sample and evaluated in the original sample. To
obtain stable results, the procedure has to be repeated multi-
ple times.For correction of too optimistic estimation of the
predictive value, we performed shrinkage of the regression
coefficients based on the difference between the apparent
and internally validated AUC.
As a fourth step, we assessed the external validity of the
new updated model by testing the performance of the




A total of 239 patients had IGT based on the first OGTT.
Mean age was 68 years (SD 10 years), 134 (56%) patients
were men, 136 (57%) had ischemic stroke, 158 (66%) had
hypertension, and 195 (82%) used statins.
Of the total of 239 patients, 118 (49%) had persistent
IGT based on the repeated OGTT performed after a
median of 46 days (IQR 33). In patients with persistent
IGT, mean BMI, HbA1c, triglycerides and LDL-levels
were significantly higher than patients with normalized
IGT. Patients with persistent IGT more frequently had
hypertension and atrial fibrillation than patients with nor-
malized IGT. (Table 1)
A total of 105 patients were included within 6 weeks
after TIA or ischemic stroke and 11 patients around 6
months after the event. The percentage of persistent IGT
was quite similar in both groups: 52 of the 105 patients
(50%) and 6 of the 11 patients (55%) respectively.
External Validation of Original Model
Compared to the patient characteristics of the previous
original model,4 in our present study mean age was higher,current smoking was less frequent, whereas hypertension,
statin use, TIA and large artery atherosclerosis, and small
vessel disease were more frequent. Comparing the charac-
teristics between patients with transient and those with per-
sistent IGT, we found a significant difference in percentage
of patients with atrial fibrillation, mean BMI and 2-hour
post-load glucose levels, which was not the case in the previ-
ous study.4 In addition, in our present study there was no
significant difference in percentage of statin use and in
mean age between patients with or without persistent IGT,
contrary to the previous study.
Overall, the performance of the original model was
poor with an AUC of .60, calibration slope of .22 and
intercept of -2.97 (Fig 1).11 Therefore, we developed a
new, updated model.
Model Development
The following predictors from the multivariable logistic
regression were selected for the new prediction model
after stepwise backward selection: BMI, hypertension,
statin use, atrial fibrillation, large artery atherosclerosis,
first 2-hour post-load glucose levels, and HbA1c levels.
(Table 2) The AUC of the newly developed model was
0.72 and the internally validated bootstrapped AUC .66.
For correction of too optimistic estimation of the predic-
tive value, shrinkage of the regression coefficients was
performed (Table 3).
The risk of persistent IGT in patients with ischemic stroke
or TIA can be calculated as follows: exp(linear predictor)/(1
+ exp[linear predictor]). Linear predictor = -7.4706 + .0529 £
BMI + .3924 £ hypertension + .3668 £ statin use + .8444 £
atrial fibrillation + .2598£ 2-hour post-load glucose lev-
els + .0793£Hba1c + .3579£ large artery atherosclerosis.
The model was externally validated in the population
of the previous original model, which showed the dis-
criminative ability (AUC) of .71, calibration slope of 1.15
and intercept of .3 (Fig 2).
Discussion
In our study, 118 of the 239 patients (49%) with IGT
after a minor ischemic stroke or TIA had persistent IGT in
the 2 to 12 weeks after initial assessment. Our original pre-
diction model did not perform well in our new dataset.
Therefore, we developed a new updated prediction model
that more accurately predicts persistent IGT in patients
with minor ischemic stroke or TIA. The predictors were
BMI, hypertension, statin use, atrial fibrillation, large
artery atherosclerosis, 2-hour post-load glucose levels and
HbA1c levels. The prediction model still performed well
when we externally validated it in the population of our
previous study,4 which had a comparable proportion of
patients with persistent IGT of 47%.
Age, current smoking, triglycerides and fasting plasma
glucose were not predictors in our study, in contrast to our
previous study.4 Possible reasons are that increasing age










Age, years (SD) 68 (10) 68 (10) 69 (11) .30
Sex (male), n (%) 134 (56%) 70 (58%) 64 (54%) .57
Vascular risk factors
Current smoking, n (%) 35 (15%) 16 (13%) 19 (16%) .53
BMI in kg/m2, mean (SD) 27 (4) 26 (4) 28 (4) <.01
Hypertension, n (%) 158 (66%) 71 (59%) 87 (74%) .01
Statin use, n (%) 195 (82%) 94 (78%) 101 (86) .12
Atrial fibrillation, n (%) 24 (10%) 6 (5%) 18 (15%) <.01
Vascular history
Ischemic cardiovascular disease, n (%) 72 (30%) 37 (31%) 35 (30%) .88
Event
Ischemic stroke, n (%) 136 (57%) 68 (56%) 68 (58%) .82
TOAST classification .09
Large artery atherosclerosis, n (%) 33 (14%) 14 (12%) 19 (16%)
Cardioembolism, n (%) 26 (11%) 8 (7%) 18 (15%)
Small vessel occlusion, n (%) 117 (49%) 61 (50%) 56 (48%)
Other determined etiology, n (%) 2 (1%) 1 (1%) 1 (1%)
Unknown, n (%) 60 (25%) 37 (31%) 23 (20%)
Glucose assessment during admission/
visiting TIA clinic
Fasting glucose levels, mean (SD),
mmol/L
5.5 (.5) 5.5 (.5) 5.5 (.8) .35
2-hour postload glucose levels, mean
(SD), mmol/L
9.1 (1) 8.9 (.8) 9.4 .9) <.01
HbA1c, mean (SD), mmol/mol 38 (3) 37 (3.3) 38 (3.1) <.01
Days between event and first OGTT,
median (IQR)
46 (33) 44 (30) 47 (36) .69
Lipid profile
Total cholesterol, mean (SD), mmol/L 5 (1.2) 5.0 (1.2) 4.9 (1.1) .35
Triglycerides, mean (SD), mmol/L 1.5 (.7) 1.3 (.7) 1.4 (.7) .05
HDL-cholesterol, mean (SD), mmol/L 2.9 (1) 1.7 (.8) 1.4 (.6) <.01
LDL-cholesterol, mean (SD), mmol/L 1.3 (.6) 2.9 (1) 3 (.9) .58
Abbreviations: BMI, body mass index; HbA1c, glycolysated Haemoglobin 1c; IQR, interquartile range; OGTT, oral glucose tolerance test;
SD, standard deviation; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
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ciated with cardiovascular diseases, but perhaps not spe-
cific enough to predict IGT. Also, triglycerides in this range
are less associated with cardiovascular diseases than LDL-
cholesterol.16 In addition, 2-hour post-load glucose levels
and HbA1c levels may be a better reflection of disturbed
glucose metabolism than fasting glucose levels alone.17
However, diabetes is less frequently identified with Hba1c
levels compared with fasting glucose levels and 2-hour
post-load glucose levels.10 In addition, in our study popula-
tion of stroke patients, 2-hour post-load glucose levels and
HbA1c levels may be a better reflection of disturbed glucose
metabolism than fasting glucose levels alone.
In concordance with previous studies that tried to pre-
dict persistent IGT, 2-hour post-load glucose levels were a
significant predictor.1-3 Also, the proportion of persistent
IGT in these studies was comparable with our study and
varied between 41% - 69%. A difference was that in ourprevious original study and the other previous mentioned
studies, the OGTT was repeated at 3 months, which is later
than the median of approximately 6 weeks in our current
study. Also, the predictors of persistent IGT were different
among the studies which shows that persistent IGT is diffi-
cult to predict. Lifestyle modification after TIA or ischemic
stroke could also improve glucose metabolism,18 which
also influences the prediction of persistent IGT.
To date, we performed the only study which externally
validated a prediction model to predict persistent IGT. Our
study provides evidence that IGT in patients with ischemic
stroke or TIA is not only due to a stress reaction, but in half
of the patients can be due to underlying abnormal glucose
metabolism. It is important to predict which patients have
persistent IGT. IGT increases the risk of developing type 2
diabetes.19,20 IGT can also increase the risk of recurrent
stroke and other cardiovascular diseases5,21 and is associ-
ated with poor outcome after stroke.8,22
Figure 1. Calibration plot of external validation of previous original model in current study population, with the predictors age, current smoking, statin use, tri-
glyceride, hypertension, history of cardiovascular diseases, body mass index (BMI), fasting plasma glucose.
Table 2. Possible predictors of persistent impaired glucose
tolerance
aOR (95%CI) 95% CI
Age 1.02 .99-1.05
Male 1.42 .79-2.57
Current smoking 1.61 .69-3.79
BMI 1.08 .99-1.18
Hypertension 1.70 .92-3.13
Statin use 2.04 .96-4.33














HbA1c per mmol/mol 1.11 1.00-1.23
Abbreviations: BMI, body mass index; HbA1c, glycolysated
Haemoglobin 1c; TIA, transient ischemic attack.
Table 3. Predictors in the final model after correction for
optimism
aOR 95% CI
BMI (per kg/m2) 1.05 .99-1.12
Hypertension 1.48 .93-2.37
Statin use 1.44 .81-2.56
Atrial fibrillation 2.32 1.08-5.00
Large artery atherosclerosis 1.43 .75-2.72
2-hour postload glucose levels 1.08 1.01-1.16
Hba1c 1.30 1.03-1.63
Formula prediction model: exp(linear predictor)/(1+exp[linear
predictor]). Linear predictor = -7.4706 + .0529 £ BMI + .3924 £
hypertension + .3668 £ statin use + .8444 £ atrial fibrilla-
tion + .2598£ 2-hour postload glucose levels + .0793 £
Hba1c + .3579 £ large artery atherosclerosis.
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cose-lowering therapy. With our prediction model, one
could consider treating patients with the highest risk of
developing persistent IGT in the acute phase after TIA or
stroke. In a recent trial with nondiabetic patients withischemic stroke or TIA, the risk of stroke or myocardial
infarction was lower among patients who received piogli-
tazone in the acute phase than among patients who
received placebo, and pioglitazone was also associated
with a lower risk of diabetes.23
The Metformin and sitAgliptin in patients with IGT and
a recent TIA or minor ischemic Stroke trial is recently
completed and the results are expected soon, which is
assessing the feasibility and safety of metformin and sita-
gliptin in patients with IGT and ischemic stroke or TIA.24
The strengths of our study are that it was prospectively
designed and used easily accessible clinical variables in
Figure 2. Calibration plot of external validation of newly developed prediction model in previous study population.
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prediction model, showing a good performance. How-
ever, we had missing variables which we tried to over-
come with single imputation. Furthermore, we did not
include patients with more severe ischemic strokes, so it is
not certain whether the prediction model can also be used
in this group of patients.
In conclusion, persistent IGT can accurately be pre-
dicted with our prediction model, using BMI, hyperten-
sion, statin use, atrial fibrillation, large artery
atherosclerosis, 2-hour post-load glucose levels in the
acute phase and HbA1c levels as clinical predictors. The
model can be used to develop new strategies for second-
ary prevention in these patients.
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